GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » Cyclically Adjusted Revenue per Share

Biosyent (Biosyent) Cyclically Adjusted Revenue per Share : $1.40 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Biosyent Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biosyent's adjusted revenue per share for the three months ended in Dec. 2023 was $0.514. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $1.40 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Biosyent's average Cyclically Adjusted Revenue Growth Rate was 15.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 19.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 25.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biosyent was 40.40% per year. The lowest was 3.60% per year. And the median was 24.70% per year.

As of today (2024-05-01), Biosyent's current stock price is $6.3287. Biosyent's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.40. Biosyent's Cyclically Adjusted PS Ratio of today is 4.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biosyent was 57.95. The lowest was 3.77. And the median was 10.62.


Biosyent Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biosyent's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Cyclically Adjusted Revenue per Share Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.86 1.06 1.20 1.40

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.20 1.24 1.28 1.37 1.40

Competitive Comparison of Biosyent's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biosyent's Cyclically Adjusted PS Ratio falls into.



Biosyent Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biosyent's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.514/125.4675*125.4675
=0.514

Current CPI (Dec. 2023) = 125.4675.

Biosyent Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.154 98.604 0.196
201406 0.196 99.473 0.247
201409 0.228 99.394 0.288
201412 0.189 98.367 0.241
201503 0.181 99.789 0.228
201506 0.201 100.500 0.251
201509 0.242 100.421 0.302
201512 0.195 99.947 0.245
201603 0.197 101.054 0.245
201606 0.233 102.002 0.287
201609 0.250 101.765 0.308
201612 0.246 101.449 0.304
201703 0.197 102.634 0.241
201706 0.292 103.029 0.356
201709 0.303 103.345 0.368
201712 0.312 103.345 0.379
201803 0.236 105.004 0.282
201806 0.309 105.557 0.367
201809 0.277 105.636 0.329
201812 0.303 105.399 0.361
201903 0.233 106.979 0.273
201906 0.276 107.690 0.322
201909 0.341 107.611 0.398
201912 0.311 107.769 0.362
202003 0.320 107.927 0.372
202006 0.270 108.401 0.313
202009 0.337 108.164 0.391
202012 0.348 108.559 0.402
202103 0.457 110.298 0.520
202106 0.462 111.720 0.519
202109 0.411 112.905 0.457
202112 0.443 113.774 0.489
202203 0.439 117.646 0.468
202206 0.410 120.806 0.426
202209 0.408 120.648 0.424
202212 0.445 120.964 0.462
202303 0.384 122.702 0.393
202306 0.488 124.203 0.493
202309 0.544 125.230 0.545
202312 0.514 125.468 0.514

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biosyent  (OTCPK:BIOYF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biosyent's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.3287/1.4
=4.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biosyent was 57.95. The lowest was 3.77. And the median was 10.62.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biosyent Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biosyent's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Industry
Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent Initiates First Dividend

By GlobeNewswire GlobeNewswire 10-12-2022

BioSyent Declares Second Quarter 2023 Dividend

By GlobeNewswire GlobeNewswire 05-25-2023

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020